Bristol Myers to deploy Anthropic’s Claude AI model to accelerate drug discovery
Bristol Myers Squibb announced a partnership with Anthropic to integrate its Claude AI model for over 30,000 employees, aiming to accelerate drug discovery and development. The collaboration also explores Claude Code’s potential in research and commercial applications, aligning with broader industry trends in AI-driven pharmaceutical innovation.
Bristol Myers Squibb revealed on Wednesday that it will deploy Anthropic’s Claude AI model across its workforce of over 30,000 employees. The goal is to expedite the discovery, development, and delivery of new medicines by leveraging AI capabilities. The company is also evaluating Claude Code, Anthropic’s coding tool, to determine its utility in research, drug development, and commercial operations. This partnership reflects a broader trend in the pharmaceutical industry, where companies are increasingly adopting AI to enhance productivity. Bristol Myers Squibb’s chief digital and technology officer, Greg Mayors, emphasized that the focus extends beyond chatbot applications, targeting the untapped value locked in decades of data silos. Anthropic’s Claude model has already demonstrated superior performance in cybersecurity, surpassing existing AI systems and setting a new industry benchmark. The collaboration aligns with projections from consultancy McKinsey, which estimated that agentic AI—systems that autonomously seek human input—could boost clinical development productivity by 35% to 45% over the next five years. The move follows other major AI-driven initiatives in the sector, such as Eli Lilly’s partnership with Nvidia to improve drug success rates. By integrating advanced AI tools, Bristol Myers Squibb aims to streamline its operations and accelerate innovation in medicine development.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.